Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study

Although the direct oral anticoagulant rivaroxaban is recommended for stroke prevention in patients with non-valvular atrial fibrillation based on Phase III clinical trials, there is still a need for additional safety data from everyday clinical practice. The ROSE study was initiated to collect furt...

Full description

Saved in:

Bibliographic Details
Published in:	PloS one Vol. 15; no. 10; p. e0240489
Main Authors:	Evans, Alison, Davies, Miranda, Osborne, Vicki, Roy, Debabrata, Shakir, Saad
Format:	Journal Article
Language:	English
Published:	United States Public Library of Science 09.10.2020 Public Library of Science (PLoS)
Subjects:	Administration, Oral Aged Aged, 80 and over Anticoagulants Atrial fibrillation Atrial Fibrillation - drug therapy Bleeding Cardiac arrhythmia Clinical trials Diabetes Disease prevention Drug dosages Drug therapy Embolisms England - epidemiology Factor Xa Inhibitors - administration & dosage Factor Xa Inhibitors - adverse effects Female Fibrillation Health risks Hemorrhage Hemorrhage - chemically induced Hemorrhage - epidemiology Humans Hypertension Incidence Male Medical records Medical research Medicine and Health Sciences Patient outcomes Patients Prevention Primary care Product safety Questionnaires Risk Risk factors Rivaroxaban Rivaroxaban - administration & dosage Rivaroxaban - adverse effects Safety Safety research Secondary Care Stroke Stroke - prevention & control Thrombosis Wales - epidemiology England Wales United Kingdom United Kingdom > UK
ISSN:	1932-6203, 1932-6203
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!